Immuno-Oncology Perspectives

Immuno-oncology (IO) is one of the most important developments to arise within oncology drug development. It has the potential to improve the lives of countless patients facing cancer today and in the near future. Q2 Solutions is an oncology development partner that understands the complexity of cancer research. 

We offer an end-to-end IO solution from discovery, to clinical development, to diagnostic testing and commercialization brought to you by our multi-disciplinary teams of scientific experts (i.e., AP/molecular, biomarker, CDx, IVD, genomics, and bioinformatics), global access to a wide range of tests and technologies, all backed by a logistics infrastructure, harmonized processes and quality systems that deliver smooth and efficient sample management processes that yield on-time high quality results you can trust. 

Explore how we can support your IO clinical development needs through multiple technologies and innovative new solutions to support this new era of immuno-oncology clinical development.

2 Essential Approaches You Should be Using Now for Minimal Residual Disease Detection in Oncology
White Paper

2 Essential Approaches You Should be Using Now for Minimal Residual Disease Detection in Oncology

Minimal Residual Disease Detection: Key Considerations for Clinical Development in Oncology

View
Infographic

End-to-End Lab Services that Advance Oncology Research

Oncology Infographic

View
Video

Benefits of Genomic Testing in Immuno-oncology Clinical Trials

The Benefits of Incorporating Genomic Testing into Immuno-oncology Clinical Trials

View
Brochure

How Flow Cytometry Advances Immuno-oncology Clinical Trial Studies

Global Flow Cytometry Services

View
Insight Brief

The Pivotal Roles Genomics and Flow Cytometry Play in Immuno-oncology Clinical Development

Clinical Trials Laboratories in the Immuno-oncology Setting

View
Insight Brief

6 Key Elements of Successful Companion Diagnostic Development

Successful Companion Diagnostic Development: Current trends and recommendations

View
Insight Brief

How Immune Repertoire Sequencing Advances Immuno-oncology Biomarker Development Programs

New Opportunities for Immuno-oncology Clinical Development Programs through T cell/B cell Repertoire Profiling

View
White Paper

Proven Benefits of Gene Expression Profiling for Biomarker Discovery in Immunotherapy Trials

Gene Expression for Keeping Pace with Immuno-oncology Breakthroughs and Biomarker Identification

View